Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Sep 30, 2025 | (FY)Mar 31, 2025 | (Q6)Sep 30, 2024 | (FY)Mar 31, 2024 | (Q6)Sep 30, 2023 | (FY)Mar 31, 2023 | (Q6)Sep 30, 2022 | (FY)Mar 31, 2022 | (Q6)Sep 30, 2021 | (FY)Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | 108.96%84.35M | ---- | 8.31%40.37M | ---- | 653.98%37.27M | ---- | 167.58%4.94M | ---- | -164.19%-7.31M |
| Profit adjustment | ||||||||||
| Interest (income) - adjustment | ---- | -84.51%-1.62M | ---- | -20.60%-878K | ---- | -225.00%-728K | ---- | 62.79%-224K | ---- | -3.79%-602K |
| Investment loss (gain) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -7.10%-528K | ---- | ---493K |
| Impairment and provisions: | ---- | 53.76%24.25M | ---- | 354.13%15.77M | ---- | -60.52%3.47M | ---- | 2,749.40%8.8M | ---- | -128.23%-332K |
| -Impairment of trade receivables (reversal) | ---- | 19.07%12.79M | ---- | 2,195.51%10.74M | ---- | -94.12%468K | ---- | 2,282.63%7.96M | ---- | --334K |
| -Other impairments and provisions | ---- | 127.86%11.46M | ---- | 67.35%5.03M | ---- | 258.59%3.01M | ---- | 225.83%838K | ---- | -156.63%-666K |
| Asset sale loss (gain): | ---- | -423.68%-123K | ---- | 2,000.00%38K | ---- | 95.74%-2K | ---- | -129.19%-47K | ---- | 38.79%161K |
| -Loss (gain) on sale of property, machinery and equipment | ---- | -171.05%-27K | ---- | 2,000.00%38K | ---- | 95.74%-2K | ---- | -129.19%-47K | ---- | 38.79%161K |
| -Loss (gain) from selling other assets | ---- | ---96K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization: | ---- | 19.86%4.77M | ---- | -0.40%3.98M | ---- | -5.80%4M | ---- | 3.44%4.24M | ---- | -15.16%4.1M |
| -Amortization of intangible assets | ---- | 1.16%783K | ---- | -5.26%774K | ---- | -8.31%817K | ---- | -4.40%891K | ---- | -20.00%932K |
| Financial expense | ---- | 13.08%5.08M | ---- | 13.92%4.49M | ---- | 23.78%3.95M | ---- | 18.56%3.19M | ---- | -55.24%2.69M |
| Operating profit before the change of operating capital | ---- | 83.01%116.71M | ---- | 32.99%63.77M | ---- | 135.41%47.96M | ---- | 1,238.68%20.37M | ---- | -106.72%-1.79M |
| Change of operating capital | ||||||||||
| Inventory (increase) decrease | ---- | 348.14%8.4M | ---- | 17.97%-3.39M | ---- | -92.72%-4.13M | ---- | 33.95%-2.14M | ---- | -114.88%-3.24M |
| Accounts receivable (increase)decrease | ---- | 53.23%-75.25M | ---- | -2,281.95%-160.9M | ---- | -84.45%7.37M | ---- | 149.44%47.43M | ---- | -240.84%-95.94M |
| Accounts payable increase (decrease) | ---- | -13.23%98.32M | ---- | 57.56%113.31M | ---- | 858.50%71.92M | ---- | 125.58%7.5M | ---- | -778.14%-29.33M |
| prepayments (increase)decrease | ---- | 43.61%-14.23M | ---- | -144.08%-25.23M | ---- | 73.83%-10.34M | ---- | -57.54%-39.5M | ---- | -3,597.35%-25.08M |
| Special items for working capital changes | ---- | -74.32%-67.88M | ---- | 53.50%-38.94M | ---- | -332.63%-83.73M | ---- | -120.27%-19.35M | ---- | 461.17%95.49M |
| Cash from business operations | ---- | 228.64%66.08M | ---- | -276.83%-51.37M | ---- | 103.13%29.05M | ---- | 123.88%14.3M | ---- | -168.45%-59.89M |
| Other taxs | ---- | -67.00%-14.9M | ---- | -25.99%-8.92M | ---- | -5,903.28%-7.08M | ---- | 114.88%122K | ---- | 67.77%-820K |
| Special items of business | -81.61%5.63M | ---- | 181.83%30.62M | ---- | -369.44%-37.41M | ---- | -52.70%13.89M | ---- | 242.03%29.36M | ---- |
| Net cash from operations | -81.61%5.63M | 184.90%51.18M | 181.83%30.62M | -374.43%-60.29M | -369.44%-37.41M | 52.32%21.97M | -52.70%13.89M | 123.76%14.42M | 242.03%29.36M | -175.49%-60.71M |
| Cash flow from investment activities | ||||||||||
| Interest received - investment | ---- | 84.51%1.62M | ---- | 20.60%878K | ---- | 225.00%728K | ---- | -62.79%224K | ---- | 3.79%602K |
| Decrease in deposits (increase) | ---- | -587.85%-40.8M | ---- | 221.26%8.36M | ---- | -83.04%-6.9M | ---- | 10.96%-3.77M | ---- | ---4.23M |
| Sale of fixed assets | ---- | -36.67%57K | ---- | -40.00%90K | ---- | 18.11%150K | ---- | --127K | ---- | ---- |
| Purchase of fixed assets | ---- | 12.98%-2.15M | ---- | -115.00%-2.47M | ---- | -34.62%-1.15M | ---- | -36.76%-852K | ---- | -115.57%-623K |
| Selling intangible assets | ---- | --1.62M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Purchase of intangible assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---3.77M | ---- | ---- |
| Recovery of cash from investments | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 0.14%104.78M | ---- | --104.64M |
| Cash on investment | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -1.22%-104.25M | ---- | ---103M |
| Other items in the investment business | -26.50%34.19M | ---- | 330.37%46.52M | ---- | 105.65%10.81M | ---- | 4,304.80%5.26M | ---- | 99.00%-125K | ---- |
| Net cash from investment operations | -26.50%34.19M | -677.58%-39.65M | 330.37%46.52M | 195.80%6.87M | 105.65%10.81M | 4.57%-7.17M | 4,304.80%5.26M | -187.04%-7.51M | 99.00%-125K | -998.97%-2.62M |
| Net cash before financing | -48.38%39.82M | 121.58%11.53M | 389.93%77.14M | -460.92%-53.42M | -238.99%-26.61M | 114.10%14.8M | -34.52%19.14M | 110.92%6.91M | 188.15%29.23M | -178.46%-63.32M |
| Cash flow from financing activities | ||||||||||
| New borrowing | ---- | -66.46%32.69M | ---- | 94.65%97.46M | ---- | 24.88%50.07M | ---- | 47.22%40.1M | ---- | -57.26%27.24M |
| Refund | ---- | 26.74%-35.2M | ---- | -27.35%-48.04M | ---- | ---37.73M | ---- | ---- | ---- | ---- |
| Issuing shares | ---- | --40.9M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Interest paid - financing | ---- | -19.25%-3.64M | ---- | -21.92%-3.05M | ---- | -43.39%-2.51M | ---- | -39.98%-1.75M | ---- | -3,800.00%-1.25M |
| Dividends paid - financing | ---- | 8.23%-1M | ---- | 56.54%-1.09M | ---- | -3.58%-2.52M | ---- | -308.40%-2.43M | ---- | ---595K |
| Issuance expenses and redemption of securities expenses | ---- | ---1.1M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Other items of the financing business | -82.27%6.83M | ---7M | 634.87%38.52M | ---- | 2.12%5.24M | ---- | -63.38%5.13M | 55.51%-28.92M | 138.95%14.02M | 34.53%-65M |
| Net cash from financing operations | -82.27%6.83M | -43.72%25.4M | 634.87%38.52M | 533.98%45.13M | 2.12%5.24M | 2.14%7.12M | -63.38%5.13M | 117.44%6.97M | 138.95%14.02M | -10.28%-39.97M |
| Effect of rate | ---- | 71.47%-574K | ---- | -6.74%-2.01M | ---- | -474.75%-1.89M | ---- | -90.45%503K | ---- | 207.22%5.27M |
| Net Cash | -59.66%46.65M | 545.61%36.93M | 641.39%115.66M | -137.81%-8.29M | -188.00%-21.36M | 57.89%21.92M | -43.87%24.28M | 113.44%13.88M | 162.54%43.25M | -332.27%-103.29M |
| Begining period cash | 82.03%80.67M | -18.86%44.32M | -18.86%44.32M | 57.93%54.62M | 57.93%54.62M | 71.23%34.58M | 41.57%34.58M | -82.92%20.2M | -79.34%24.43M | 50.29%118.21M |
| Cash at the end | -20.41%127.32M | 82.03%80.67M | 381.07%159.98M | -18.86%44.32M | -43.50%33.25M | 57.93%54.62M | -13.03%58.86M | 71.23%34.58M | 37.93%67.68M | -82.92%20.2M |
| Cash balance analysis | ||||||||||
| Cash and bank balance | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --67.68M | ---- |
| Cash and cash equivalent balance | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --67.68M | ---- |
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | Dahua Ma Shiyun Certified Public Accountants Co., Ltd. | -- | Dahua Ma Shiyun Certified Public Accountants Limited | -- | Dahua Ma Shiyun Certified Public Accountants Limited | -- | Dahua Ma Shiyun Certified Public Accountants Co., Ltd. | -- | National Health Accounting Firm Limited |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.